nach oben

Calcified Tissue International

Erschienen in:

01.11.2013 | Original Research

Comparable Effects of Alendronate and Strontium Ranelate on Femur in Ovariectomized Rats

verfasst von: BaiLing Chen, YiQiang Li, XiaoXi Yang, DengHui Xie

Erschienen in: Calcified Tissue International | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

This study compared the effects of alendronate (ALN) and strontium ranelate (SR) on bone mineral density (BMD), bone histomorphometry, and biomechanics in ovariectomized (OVX) rats. We randomly assigned 48 3-month-old female Sprague–Dawley rats to four groups: sham, OVX, ALN, and SR. Rats in the OVX, ALN, and SR groups received bilateral OVX. Rats in the ALN and SR groups were orally administrated ALN (7 mg/kg/week) and SR (500 mg/kg/day). Rats in the sham and OVX groups were treated with saline. All treatments continued for 12 weeks. Femoral BMD examination, distal femoral bone histomorphometry analysis, and biomechanical tests at the femoral diaphysis and metaphysis were performed to evaluate the effects of treatments in OVX rats. Results showed that both ALN and SR significantly increased femoral BMD (total femur, diaphyseal BMD, and distal metaphyseal BMD), distal femoral bone histomorphometric parameters (BV/TV, Tb.N, and Tb.Th), and femoral biomechanical parameters (maximum load, failure load, stiffness) compared with the OVX group (P < 0.05). No differences were found between ALN and SR in increasing femoral BMD, distal femoral bone histomorphometric parameters (BV/TV, Tb.N, and Tb.Th), and femoral diaphysis biomechanical parameters (maximum load, failure load, stiffness) (P > 0.05). The SR group was inferior to the ALN group in femoral metaphysis biomechanical parameters (P < 0.05). In conclusion, ALN (7 mg/kg/week) and SR (500 mg/kg/day) have similar effects by increasing BMD, distal femoral bone histomorphometric parameters, and femoral metaphysis biomechanical properties. Although ALN has greater effects than SR on distal femoral metaphysis biomechanical properties, in general, ALN and SR have comparable effects on the femur in OVX rats.

Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276–1287PubMedCrossRef

Iacono MV (2007) Osteoporosis: a national public health priority. J Perianesth Nurs 22(3):175–182PubMedCrossRef

North American Menopause Society (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 17(1):25–54CrossRef

Christenson ES, Jiang X, Kagan R, Schnatz P (2012) Osteoporosis management in post-menopausal women. Minerva Ginecol 64(3):181–194PubMed

Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86(11):1022–1033PubMedCrossRef

Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199CrossRef

Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20(1):141–151CrossRef

Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, Schousboe JT, Cummings SR (2012) Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the fracture intervention trial. J Bone Miner Res 27(8):1804–1810PubMedCrossRef

Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44(6):1078–1084PubMedCrossRef

10.

Reginster JY (2002) Strontium ranelate in osteoporosis. Curr Pharm Des 8(21):1907–1916PubMedCrossRef

11.

Marie PJ (2005) Strontium ranelate: a novel mode of action optimizing bone formation and resorption. Osteoporos Int 16(Suppl 1):S7–S10PubMedCrossRef

12.

Bonnelye E, Chabadel A, Saltel F, Jurdic P (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42(1):129–138PubMedCrossRef

13.

Ma YL, Zeng QQ, Porras LL, Harvey A, Moore TL, Shelbourn TL, Dalsky GP, Wronski TJ, Aguirre JI, Bryant HU, Sato M (2011) Teriparatide [rhPTH(1–34)], but not strontium ranelate, demonstrated bone anabolic efficacy in mature, osteopenic, ovariectomized rats. Endocrinology 152(5):1767–1778PubMedCrossRef

14.

Fuchs RK, Allen MR, Condon KW, Reinwald S, Miller LM, McClenathan D, Keck B, Phipps RJ, Burr DB (2008) Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19(9):1331–1341PubMedCrossRef

15.

Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM (2007) The calcium-sensing receptor (CaR) is involved in strontium ranelate–induced osteoblast proliferation. Biochem Pharmacol 74(3):438–447PubMedCrossRef

16.

Caverzasio J (2008) Strontium ranelate promotes osteoblast cell replication through at least two different mechanisms. Bone 42(6):1131–1136PubMedCrossRef

17.

Pi M, Quarles LD (2004) A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J Bone Miner Res 19(5):862–869PubMedCrossRef

18.

Atkins GJ, Welldon KJ, Halbout P, Findlay DM (2009) Strontium ranelate treatment of primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20:653–664PubMedCrossRef

19.

Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS (2009) Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 157(7):1291–1300PubMedCrossRef

20.

Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350(5):459–468PubMedCrossRef

21.

Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822PubMedCrossRef

22.

Kanis JA, Johansson H, Oden A, McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and nonvertebral fracture in postmenopausal osteoporosis and the interaction with FRAX^®. Osteoporos Int 22(8):2347–2355PubMedCrossRef

23.

Liu JM, Wai-Chee Kung A, Pheng CS, Zhu HM, Zhang ZL, Wu YY, Xu L, Meng XW, Huang ML, Chung LP, Hussain NH, Sufian SS, Chen JL (2009) Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis. Bone 45(3):460–465PubMedCrossRef

24.

Rizzoli R, Laroche M, Krieg MA, Frieling I, Thomas T, Delmas P, Felsenberg D (2010) Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 30(10):1341–1348PubMedCrossRef

25.

Rizzoli R, Chapurlat RD, Laroche JM, Krieg MA, Thomas T, Frieling I, Boutroy S, Laib A, Bock O, Felsenberg D (2012) Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporos Int 23(1):305–315PubMedCrossRef

26.

Sun P, Cai DH, Li QN, Chen H, Deng WM, He L, Yang L (2010) Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats. Calcif Tissue Int 86(6):495–501PubMedCrossRef

27.

National Research Council, Committee for the Update of the Guide for the Care and Use of Laboratory Animals (2011) Guide for the care and use of laboratory animals, 8th edn. National Academies, USA

28.

Chen BL, Li YQ, Xie DH, Yang XX (2012) Low-magnitude high-frequency loading via whole body vibration enhances bone implant osseointegration in ovariectomized rats. J Orthop Res 30(5):733–739PubMedCrossRef

29.

Chen B, Li Y, Yang X, Xie D (2012) Femoral metaphysis bending test of rat: introduction and validation of a novel biomechanical testing protocol for osteoporosis. J Orthop Sci 17(1):70–76PubMedCrossRef

30.

Sliwiński L, Janiec W, Pytlik M, Folwarczna J, Kaczmarczyk-Sedlak I, Pytlik W, Cegieła U, Nowińska B (2004) Effect of administration of alendronate sodium and retinol on the mechanical properties of the femur in ovariectomized rats. Pol J Pharmacol 56(6):817–824PubMed

31.

Seedor JG, Quartuccio HA, Thompson DD (1991) The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. Bone Miner Res 6(4):339–346CrossRef

32.

Wang Y, Huang P, Tang PF, Chan KM, Li G (2011) Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. J Orthop Surg Res 6:34PubMedCrossRef

33.

Ahmet-Camcioglu N, Okman-Kilic T, Durmus-Altun G, Ekuklu G, Kucuk M (2009) Effects of strontium ranelate, raloxifene and misoprostol on bone mineral density in ovariectomized rats. Eur J Obstet Gynecol Reprod Biol 147(2):192–194PubMedCrossRef

34.

Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P (2009) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 20(8):1417–1428PubMedCrossRef

35.

Ulrich U, Miller P, Eyre D, Chesnut CR, Schlebusch H, Soules M (2003) Bone remodeling and bone mineral density during pregnancy. Arch Gynecol Obstet 268:309–316PubMedCrossRef

36.

Chachra D, Lee JM, Kasra M, Grynpas MD (2000) Differential effects of ovariectomy on the mechanical properties of cortical and cancellous bone in rat femora and vertebrae. Biomed Sci Instrum 36:123–128PubMed

37.

Thongchote K, Charoenphandhu N, Krishnamra N (2008) High physiological prolactin induced by pituitary transplantation decreases BMD and BMC in the femoral metaphysis, but not in the diaphysis of adult female rats. J Physiol Sci 58:39–45PubMedCrossRef

38.

Yaffe A, Kollerman R, Bahar H, Binderman I (2003) The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. J Periodontol 74(1):44–50PubMedCrossRef

39.

Nijenhuis T, van der Eerden BC, Hoenderop JG, Weinans H, van Leeuwen JP, Bindels RJ (2008) Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5^−/− mice. J Bone Miner Res 23(11):1815–1824PubMedCrossRef

40.

Licata AA (1997) Bisphosphonate therapy. Am J Med Sci 313(1):17–22PubMedCrossRef

Titel: Comparable Effects of Alendronate and Strontium Ranelate on Femur in Ovariectomized Rats
verfasst von: BaiLing Chen
YiQiang Li
XiaoXi Yang
DengHui Xie
Publikationsdatum: 01.11.2013
Verlag: Springer US
Erschienen in: Calcified Tissue International / Ausgabe 5/2013
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-013-9765-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients

Teriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I

Cystic Bone Angiomatosis: A Case Report Treated with Aminobisphosphonates and Review of the Literature

Association Between Aortic Calcification and the Risk of Osteoporosis in a Chinese Cohort: The Chongqing Osteoporosis Study

A 12-Year Ecological Study of Hip Fracture Rates among Older Taiwanese Adults